New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
14:01 EDTACORAcorda Therapeutics sees FY13 AMPYRA U.S. net sales $285M-$315M
Sees other revenue of $25M (FAMPYRA and Zanaflex), which includes $9.1M in amortized license revenue. Comment from slides that will be presented at the 31st Annual JP Morgan Healthcare Conference.
News For ACOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
07:35 EDTACORNewYorkBio to hold a conference
Subscribe for More Information
May 1, 2015
12:26 EDTACORBiogen patent challenged by Kyle Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 1-20 of US patent 8,399,514 held by Biogen (BIIB), according to a USPTO filing. The patent is related to the company's multiple sclerosis drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Celgene (CELG), Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). PRICE ACTION: Shares of Biogen are up 3% to $385.29 in afternoon trading.
April 30, 2015
06:05 EDTACORAcorda Therapeutics backs FY15 Ampyra sales $405M-$420M
Backs FY15 R&D guidance of $150M-$160M; Backs FY15 SG&A guidance of $180M-$190m.
06:05 EDTACORAcorda Therapeutics reports Q1 Ampyra sales $92.4M
Subscribe for More Information
06:04 EDTACORAcorda Therapeutics reports Q1 non-GAAP EPS 15c, consensus 14c
Subscribe for More Information
April 23, 2015
09:20 EDTACORCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 110 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The 501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
April 22, 2015
07:33 EDTACORAcorda Therapeutics presents data on remyelinating anibody clinical study
Subscribe for More Information
07:19 EDTACORAcorda Therapeutics assumed with a Neutral at Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use